Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11

Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11 — Trials · CancerIndex

Clinical trials

Registered studies

21 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2
Recruiting: 1
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: M.D. Anderson Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00801489	Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	recruiting	Phase 2	270	M.D. Anderson Cancer CenterOTHER	1	Sep 18, 2026	clinicaltrials
NCT00658814	Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia	active not recruiting	Phase 2	133	National Cancer Institute (NCI)NIH	1